Comparative in vitro bactericidal activity between cefepime and ceftazidime, alone and associated with amikacin, against carbapenem-resistant Pseudomonas aeruginosa strains

Diagnostic Microbiology and Infectious Disease

Volumn 37, Issue 1, 2000, Pages 41-44

  Bantar, Carlos ^a   Di Chiara, Marcela ^a   Nicola, Federico ^a   Relloso, Silvia ^a   Smayevsky, Jorgelina ^a  

^a Centro Nacional de Genetica Medica de Buenos Aires   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CARBAPENEM DERIVATIVE; CEFEPIME; CEFTAZIDIME;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA;

AMIKACIN; ANTI-BACTERIAL AGENTS; CARBAPENEMS; CEFTAZIDIME; CEPHALOSPORINS; DRUG RESISTANCE, MICROBIAL; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA;

EID: 0034090663     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0732-8893(99)00156-X     Document Type: Article

References (13)

1. Bantar C., Micucci M., Fernandez Canigia L., Smayevsky J., Bianchini H. Synergy characterization for Enterococcus faecalis strains displaying moderately high-level gentamicin and streptomycin resistance. J Clin Microbiol. 31:1993;1921-1923.
2. Barradell L.B., Bryson H.M. Cefepime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs. 47:1994;471-505.
3. Bouza E., García-Garrote F., Cercenado E., Marín M., Díaz M.S. Pseudomonas aeruginosa A survey of resistance in 136 hospitals in Spain. Antimicrob Agents Chemother. 43:1999;981-982.
4. Gradelski E., Fung-Tomc J., Huczko E., Kessler R.E. Development of resistance in Pseudomonas aeruginosa to broad-spectrum cephalosporins via step-wise mutations. J Antimicrob Chemother. 32 (suppl B:1993;75-80.
5. Jarvis W.R., Martone M. Predominant pathogens in hospital infections. J Antimicrob Chemother. 29 (suppl A:1992;19-24.
6. Johnson C.C., Livornese L., Gold M.J., Pitsakis P.G., Taylor S., Levinson M.E. Activity of cefepime against ceftazidime-resistant Gram-negative bacilli using low and high inocula. Antimicrob Agents Chemother. 35:1995;765-773.
7. Jones R.N., Pfaller M.A., Doern G.V., Erwin M.E., Hollis R.J. Antimicrobial activity and spectrum investigation of eight broad-spectrum β-lactam drugs A 1997 surveillance trial in 102 medical centers in the United States. Cefepime Study Group Diagn Microbiol Infect Dis. 30:1998;215-228.
8. Köhler T., Michea-Hamzehpour M., Epp S.F., Pechere J.C. Carbapenem activities against Pseudomonas aeruginosa Respective contributions of Opr D and efflux systems. Antimicrob Agents Chemother. 43:1999;424-427.
9. Kuikka A., Valtonen V.V. Factors associated with improved outcome of Pseudomonas aeruginosa bacteriemia in a Finnish University Hospital. Eur J Clin Microbiol Infect Dis. 17:1998;701-708.
10. Mimoz O., Jacolot A., Padoin C., Tod M., Samii K., Petitjean O. Cefepime and amikacin synergy in vitro and in vivo against a ceftazidime-resistant strain of Enterobacter cloacae. Antimicrob Agents Chemother. 41:1998;367-372.
11. Nakae T., Nakajima A., Ono T., Saito K., Yoneyama H. Resistance to β- lactam antibiotics in Pseudomonas aeruginosa due to interplay between the MexAB-Opr M efflux pump and β- lactamase. Antimicrob Agents Chemother. 43:1999;1301-1303.
12. National Committee for Clinical Laboratory Standards (1997). Methods for dilution antimicrobial susceptibility test for bacteria that grow aerobically. Approved standard M7-A4. National Committee for Clinical Laboratory Standards, Villanova, Pa.
13. Troillet N., Samore M.H., Carmeli Y. Imipenem-resistant Pseudomonas aeruginosa Risk factors and antibiotic susceptibility patterns. Clin Infect Dis. 25:1997;1094-1098.